CancerRadarCancerRadar
RadiopharmaceuticalFDA-approvedSecond-line

Lutetium Lu 177 vipivotide tetraxetan

Generic name: lutetium lutetium-177 vipivotide tetraxetan

How it works

Delivers targeted radiation to prostate cancer cells, causing cell death.

Cancer types

Prostate Cancer

Efficacy

Studies show that lutetium Lu 177 vipivotide tetraxetan can slow disease progression in patients with metastatic castration-resistant prostate cancer.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.